Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Dexmedetomidine and Propofol-Remifentanil Conscious Sedation for Awake Craniotomy for Tumor Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients more than 18 years of age.~* ASA score I, II and III.~* Patients scheduled to undergo awake craniotomy for elective tumor resection.~Exclusion Criteria:~* Patients with allergies to the drugs being used.~* Patients who are pregnant.~* Patients with alcohol or substance abuse.~* Patients who are not able to understand the instructions for an awake craniotomy and questions regarding intra-operative pain, and post-operative satisfaction.~* Lack of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Propofol-Remifentanil (Type: ACTIVE_COMPARATOR): Group I. (propofol/remifentanil): Infusions begin at remifentanil (0.01-0.1 mcg/kg/min) and propofol (25-250 mcg/kg/min) for 15 min, and then titrated to effect.
- Dexmedetomidine (Type: EXPERIMENTAL): Group II. (dexmedetomidine): The infusion begins at 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.

Based on this trial design, predict the completion outcome and termination type (if applicable).